PMID- 35149166
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20240102
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 185
DP  - 2022 Mar
TI  - Pancreatic cancer-associated diabetes mellitus is characterized by reduced beta-cell 
      secretory capacity, rather than insulin resistance.
PG  - 109223
LID - S0168-8227(22)00035-3 [pii]
LID - 10.1016/j.diabres.2022.109223 [doi]
AB  - AIMS: The early distinction of pancreatic cancer associated diabetes (PaCDM) in 
      patients with elderly diabetes is critical. However, PaCDM and type 2 diabetes 
      mellitus (T2DM) remain indistinguishable. We aim to address the differences 
      between the pancreatic and gut endocrine hormones of patients with PaCDM and 
      T2DM. METHODS: A total of 44 participants underwent mixed meal tolerance test 
      (MMTT). Fasting and postprandial concentrations of insulin, C-peptide, glucagon, 
      pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1), and gastric 
      inhibitory peptide (GIP) were measured. Insulin sensitivity and secretion indices 
      were calculated. One-way ANOVA with post-hoc analysis was used for statistical 
      analysis. RESULTS: Insulin and C-peptide responses to MMTT were blunted in PaCDM 
      patients compared with T2DM. Baseline concentrations and AUCs differed. PaCDM 
      patients showed lower insulin secretion capacity but better insulin sensitivity 
      than T2DM patients. The peak concentration and AUC of PP in T2DM group were 
      higher than healthy controls, but in accordance with PaCDM. PaCDM patients 
      presented lower baseline GLP-1 concentration than T2DM patients. No between-group 
      differences were found for glucagon and GIP. CONCLUSIONS: PaCDM patients had a 
      lower baseline and postprandial insulin and C-peptide secretion than T2DM 
      patients. Reduced insulin secretion and improved peripheral sensitivity were 
      found in PaCDM patients compared with T2DM.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Bao, Jiantong
AU  - Bao J
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Liu, Dechen
AU  - Liu D
AD  - Department of Endocrinology, School of Medicine, and Department of Clinical 
      Science and Research, Zhongda Hospital, Southeast University, Nanjing, China.
FAU - Sun, Jinfang
AU  - Sun J
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing, China. Electronic 
      address: 101011574@seu.edu.cn.
FAU - Su, Xianghui
AU  - Su X
AD  - Department of Endocrinology, Changji Branch, First Affiliated Hospital of 
      Xinjiang Medical University, Xinjiang 831100, China.
FAU - Cheng, Hao
AU  - Cheng H
AD  - Department of Hepatobiliary and Pancreatic Surgery, Nanjing Drum Tower Hospital, 
      The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Qi, Liang
AU  - Qi L
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Zhang, Yidi
AU  - Zhang Y
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Lv, Yingqi
AU  - Lv Y
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Ye, Zheng
AU  - Ye Z
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Yu, Xuebing
AU  - Yu X
AD  - Department of Endocrinology, Changzhou Jintan District People's Hospital, School 
      of Medicine in Jiangsu University, Changzhou, China.
FAU - Wei, Qiong
AU  - Wei Q
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Qiu, Yudong
AU  - Qiu Y
AD  - Department of Hepatobiliary and Pancreatic Surgery, Nanjing Drum Tower Hospital, 
      The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Su, Jianhua
AU  - Su J
AD  - Changzhou Jintan District People's Hospital, School of Medicine in Jiangsu 
      University, Changzhou, China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China. Electronic address: lingli@seu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220208
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - C-Peptide
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Gastric Inhibitory Polypeptide
MH  - Glucagon
MH  - Glucagon-Like Peptide 1
MH  - Humans
MH  - Insulin
MH  - *Insulin Resistance
MH  - *Pancreatic Neoplasms
OTO - NOTNLM
OT  - Pancreatic cancer
OT  - Pancreatic islet function
OT  - Pancreatogenic diabetes
EDAT- 2022/02/13 06:00
MHDA- 2022/04/20 06:00
CRDT- 2022/02/12 05:29
PHST- 2021/06/18 00:00 [received]
PHST- 2021/10/19 00:00 [revised]
PHST- 2022/01/28 00:00 [accepted]
PHST- 2022/02/13 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/02/12 05:29 [entrez]
AID - S0168-8227(22)00035-3 [pii]
AID - 10.1016/j.diabres.2022.109223 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Mar;185:109223. doi: 10.1016/j.diabres.2022.109223. 
      Epub 2022 Feb 8.